CompletedPHASE2, PHASE3NCT04274257

A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tokyo University
Principal Investigator
Ayumi Yoshizaki, MD, PhD
Tokyo University
Intervention
Double-Blind Placebo(drug)
Enrollment
56 enrolled
Eligibility
20-80 years · All sexes
Timeline
20172019

Study locations (4)

Collaborators

Japan Agency for Medical Research and Development · Zenyaku Kogyo Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04274257 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials